Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349075 · ClinicalTrials.gov registry record
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- 474
- Enrollment target
NCT01349075 is a clinical trial that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 474 participants.
The verdict
NCT01349075 has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- 474 participants
- Enrollment target
Study Summary
TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a blood vessel. This allows a large local dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue.
Interventions
- RADIATION TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2007-10 |
| Est. Completion | 2021-03-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349075
The ClinicalTrials.gov registry entry for NCT01349075 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere is the first listed.
NCT01349075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349075 about?
NCT01349075 is a clinical study titled "TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma". TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a blood vessel. This allows a large local dose of radiation to be deliver...
What is the current status of trial NCT01349075?
This trial is currently completed. The enrollment target is 474 participants. The study started on 2007-10. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT01349075?
The interventions under investigation include: TheraSphere (RADIATION).
Who is sponsoring clinical trial NCT01349075?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.